WE ARE WHAT WE DO

Juan M. Campos is a Medical Device professional with 30 years of continued industry experience.His main areas of expertise include Quality Assurance, Regulatory Compliance and Regulatory Affairs. He has led culturally and geographically diverse QA/RA teams in Spain, UK, France, Switzerland, Netherlands, Germany, Portugal, Italy, Greece and Turkey directly reporting to him. Additionally, he has successfully coordinated global QA/RA projects with extended on site presence in USA and China. Most of the Regulations that govern today’s Medical Device world (EU Medical Device Directive, US FDA CFR 21-820, ISO 13485, Japan MHLW, Australia TGA, Brazil ANVISA, Health Canada, China SFDA, etc) have been created, implemented and even revised several times during Juan’s 30 year daily industry activity in leadership QA/RA roles. Specifically Juan has successfully led both product international Regulatory Registration processes, together with Regulatory Compliance global projects to ensure full Quality System compliance with those Regulations (Quality System design and implementation, Regulatory Agency pre-inspection readiness, Regulatory Agency post inspection remediation, M&A due diligence and post-merger integration, product quality claims & liability, etc) in manufacturing, subcontractor and distribution facilities around the globe. Juan is also a certified SGS ISO 9001 Auditor, BSI ISO 13485 Lead Auditor with extensive EMEA, China and USA on site audit experience, and an active voting member of ISO TC150 CTN91 Implants and ISO TC210 CTN111 SC3 Quality Management Committees.

Telecommunications engineer degree at La Salle (Ramon Llull University), Barcelona 1984. Master’s degree in Total Quality Management at Polytechnical Catalonia University (UPC), Barcelona 1994. Executive MBA degree at La Salle (Ramon Llull University) Barcelona, and St. Mary’s College (San Francisco - California), 2004 He has more than 30 years of work experience, most of them as Industrial Director in Medical Device business. He has led all the operative areas as Production, Maintenance, Quality Control, Supply Chain, Engineering and R&D, always in multinational or big family companies. He has huge expertise in process automation and process outsourcing in countries like India, China, and Tunisia. He has successfully implemented several projects of Lean Manufacturing, 5S, TPM, and continuous improvement (Kaizen).

Hendrik has a master’s degree in Electronic Engineering and PhD in Biomedical Engineering from the University of Ghent, Belgium. He has over 25 years of experience in the development of innovative medical device technologies in early start-ups and in large size international companies. He has experience in the field of cardiac, vascular and neurological therapies, always with the aim of creating new standards of care. After his initial steps as Field Clinical Engineer, he became the Vice-President of Clinical & Regulatory Affairs at Endosense, which was acquired by St Jude Medical (now Abbott), to develop and execute the global clinical-regulatory strategy. After that, and just prior to joining Anaconda Biomed, he was the co-founder and Vice-President of Clinical & Regulatory Affairs at ONWARD Medical in Lausanne, Switzerland, developing solutions for people with spinal cord injury. Hendrik is passionate about setting up clinical studies to bring innovative, Class III technical solutions to the patients and the medical community. He is also Associated Teaching Professor at the University of Ghent in Belgium.

Neurology degree at Hospital Vall d’Hebron, Barcelona 2003. Stroke Fellowship at University of Texas- Houston (2004-5). PhD in Medicine at Universtitat Autònoma de Barcelona (2004). He developed his professional activity in the field of cerebrovascular diseases with special interest in the acute phase of ischemic stroke and particularly in promoting reperfusion treatments either systemic or endovascular. His research activity in the acute phase of stroke includes a large experience in the design of clinical trials, research projects with public or private funding, direction of several doctoral thesis, and signing more than 150 peer reviewed publications. His research activity also includes the development of telemedicine solutions to increase and accelerate the access to best therapies to all acute stroke patients.

Dr. Jovin is an expert in interventional and non-interventional treatments for the entire spectrum of cerebrovascular disorders, including ischemic and hemorrhagic stroke. He is currently Medical Director, Neuroscience Service Line, Professor and Chair, Department of Neurology, Cooper University Health Care, Camden, New Jersey. He serves as principal investigator for the recently halted REVASCAT study, a randomized trial in Spain of endovascular therapy versus medical therapy for stroke due to large artery occlusion within 8 hours, as well as principal investigator for DAWN, a multicenter, international, randomized trial of endovascular therapy versus medical therapy in the beyond 8-hour time window. He is a member of the executive/steering committee for several multicenter national and international trials and is the site principal investigator/co-investigator for several local or multi-center clinical trials. He has published more than 150 articles in peer-reviewed journals or book chapters. As the former UPMC Stroke Fellowship Program Director and UPMC Neurointerventional Fellowship Program Director, positions he has held for over five years, Dr. Jovin has significant experience in mentoring young neurologists or neurosurgeons who, in addition to acquiring the necessary clinical and procedural skills for successful clinical practice, have authored numerous publications in leading peer-reviewed cerebrovascular disease journals. Dr. Jovin serves as Past President of the Society of Vascular and Interventional Neurology (SVIN)and serves on several other committees or boards of national and international societies (American Academy of Neurology, American Society of Neuroimaging,) and editorial boards of medical journals within his area of expertise (Stroke, Journal of Neuroimaging, Interventional Neurology). Dr. Jovin's clinical and research activities are focused on the care of patients with cerebrovascular disorders.

Dr. Nogueira completed his Neurology Residency at the Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital/ Harvard Medical School in 2002. He subsequently completed Fellowships in Vascular and Critical Care Neurology as well as Neurointerventional Surgery at the MGH where he remained as a faculty member for five additional years. He moved to Atlanta in September 2010 to help building the Marcus Stroke & Neuroscience Center at the Grady Memorial Hospital where he serves as the Director of the Neuroendovascular Service. He is Editor-in-Chief for the Interventional Neurology Journal and the Past President of the Society of Vascular and Interventional Neurology (SVIN). He has been involved in many of the mechanical thrombectomy trials for acute stroke. He was the Principal Investigator of the DAWN, Penumbra 3D Separator, and TREVO-2 trials and a Steering Committee member for the SWIFT, SWIFT Prime, and ARISE-II trials. He is currently the Principal Investigator for the RESILIENT and ENDOLOW trials. He has published over 250 manuscripts in peer-reviewed medical journal including NEJM, the Lancet, JAMA, Neurology, Stroke, AJNR, JAMA Neurology, and Circulation amongst others. He specializes in the treatment of cerebrovascular diseases including ischemic stroke, brain aneurysm, cerebral and spinal vascular malformations, and intracranial and extracranial stenosis.

Tommy Andersson MD, PhD, is qualified as a specialist in Neurological Surgery and Neuroradiology, presently Professor and Senior Consultant in Neurointervention at AZ Groeninge, Kortrijk, Belgium, and at the Karolinska University Hospital, Stockholm, Sweden. He is the Director for Education in Neuroendovascular treatment at Karolinska, Shared Director for the Section of Neurointervention and angiography at KERIC (Karolinska Experimental Research and Imaging Centre), Chairman of the ESMINT Examination Committee as well as of the Swedish national quality registry EVAS (EndoVascular therapy for Acute ischemic Stroke) and the former Chairman of the Swedish Society of Neuroradiology. Prof Andersson received his medical training and certificates at Karolinska Institute in Stockholm and was between 2000 and 2002 fellow in Vascular Neurosurgery and Interventional Neuroradiology at the Departments of Neurosurgery and Medical Imaging, Toronto Western Hospital, Toronto, Canada. He has been the PI for several international multicentre studies and an invited speaker at international conferences more than 300 times in the last 15 years. Prof Andersson has organised more than 40 courses in management of acute stroke patients for European physicians, supervised a large number of Master- and PhD-students and is the author of numerous peer-reviewed articles and book chapters.

Prof. Dr. Christophe Cognard – Prof. Christophe Cognard is the Chairman of the Department of Diagnostic and Therapeutic Neuroradiology, University Hospitals Purpan and Rangueil since Dec. 2002 at university Paul Sabatier of Toulouse, France. He is also the Professor of Radiology at the same University since Sept. 1999. Prof Cognard, with a Fellowship in Radiology (1989 to 1992) and a Thesis of Medicine on Cerebral dural arterio-venous fistulas: clinical and angiographic correlation with a revisited classification of venous drainage (Director P. Gobin, President J.J. Merland), Sept. 1992 has been developing his professional and research career in Diagnostic and Therapeutic Neuroradiology for 30 years. Dr. Cognard has held the position of General Secretary of the ESMINT (European Society of Minimal Invasive Neurological Therapies) from 2010 to 2012 and President from 2012 to 2014. Related to this, Dr. Cognard has also held the positions of President (2009 and 2010), Co-President (2011 to 2014) and General Secretary (2010 to 2012) of the Annual Congress of the ESMINT, Nice, France. Before, in 2009 he was the President of the Annual Congress of the French Society of Neuroradiology (SFNR). He has over 150 publications in scientific journals, 22 didactic articles and 6 book chapters.

We are investors in companies that make the difference. We trust in great entrepreneurs; we partner with hard-working visionaries. Innogest is a Venture Capital firm focused on seed and early-stage ventures, with more than € 200 milion of capital under management. We have over 100 years of cumulative professional experience in the digital and the healthcare fields. Innogest invests in high potential companies through a direct share in their equity and pays special attention to market potential and size. Innogest leverages its extensive network of contacts, working alongside its partners through its offices in Turin, Milan, and San Francisco. Our mission is to generate high-level returns for our investors by turning entrepreneurship and technology into fast-growing and successful companies.

Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies with a special focus on pharmaceuticals, diagnostics, and medical devices. Founded in 2008, Ysios Capital currently manages about €200M ($220M) distributed across two funds: Ysios BioFund I, fully invested, and Ysios BioFund II Innvierte. Ysios Capital is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe.

We are life sciences investors. We invest in biotechnology and medical device companies in North America and Western Europe. We have invested in early-stage, disruptive and scalable platform technologies, as well as therapeutics companies with defined products. We invest in both private and public companies via primary investments, PIPEs, and direct secondaries. Omega has a strategic relationship with NeoMed Management, a Jersey headquartered investment firm, which broadens our capabilities within key European markets and adds expertise in additional therapeutic areas and in medical devices. NeoMed will continue to manage its existing legacy funds, while assisting and advising on new investments for Omega’s current fund. Omega’s investments have brought to market 28 products.

Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies.

Rich Ferrari is a Co-Founder of De Novo Ventures, a premier firm dedicated to Medical Devices and Biotechnology with $650 million under management. He has raised over a billion dollars for companies he has directly influenced and participated in acquisition events worth approximately $1.8 billion. Rich served as CEO and Chairman of PQ Bypass, which was acquired by Endologix for $350Mill. He was also a successful CEO of two publicly traded medical technology companies, Cardiovascular Imaging Systems, and CardioThoracic Systems. Rich is the co-founder of multiple medical device companies such as MTG Group, IVS, and Transaortic. He is a board member of various medical device companies and has received the Mallinckrodt Award for Excellence in Medicine. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.

Raúl holds a bachelor’s of science in biological sciences from UPV/EHU and a PhD in neurosciences from UPV/EHU and CSIC. He worked on central nervous system pharmacology in the department of pharmacology of the University of the Basque Country, and on neurochemistry in the department of neurochemistry of the Institute for Biomedical Research of Barcelona, Spanish National Research Council . Raúl coordinates the identification and evaluation of investment opportunities from the scientific and business perspectives. He also directs the preparation of the scientific and business reporting to the Investment Committee and collaborates in the monitoring of Ysios’s portfolio companies. Raúl serves on the board of MedLumics, Anaconda Biomed and Corwave. Formerly he was board member at Prexton Therapeutics, acquired by Lundbeck, and STAT-Dx, acquired by Qiagen. Prior to joining Ysios in 2008, Raúl worked at Almirall where he was responsible for managing and developing the company’s business through licensees and distributors in America and Africa.

Sylvain Sachot is principal at Asabys Partner. Sylvain joined Asabys in 2018 from Ysios Capital, where he was an associate responsible for sourcing and diligence of investment opportunities in the fields of biopharmaceuticals and medical technologies. Previously, Sylvain was a postdoctoral fellow in the department of Genetics and Genomic Sciences at the Mount Sinai School of Medicine in New York. He obtained his Ph.D. in Molecular Medicine from University of Nantes in 2009. Biotechnologist by training, Sylvain particularly focused during his (post)doctoral studies in the field of gene and cell therapy and lysosomal storage disorders. Sylvain obtained his master’s degree in biotechnology with honours from University Paris XII. He also completed an MBA at Esade Business School in Barcelona in 2014.

Pharmacist degree at University Rene Descartes - Paris V, Paris 1991. Master’s in Business Administration at IESE, Barcelona 1997. PhD in Epidemiology (Pharmacy) University Rene Descartes - Paris V, Paris 1994. Dr. François Salmon has more than 15 years of experience in the medical device industry working for major and startup companies. After being Franchise Director at Cordis Spain (Johnson & Johnson) and General Manager at Molnlycke Health Care Iberia, he drove successfully all the operations prior to the acquisition of Endosense by St Jude Medical, built for the company a direct sales force, outsourcing manufacturing, designing next generation, and obtaining FDA approval. Supported a team of close to 200 people and sales target of $160 million as VP Southern Region at CR Bard before joining Anaconda Biomed S.L. as CEO.

Claudio Nessi holds an MBA from Erasmus University, the Netherlands, and is a Ph.D. degree in Genetics from the University of Pavia, Italy. Claudio has been a board member of Axovan AG, Creabilis SA, Endosense SA, Kuros BioSurgery AG and PregLem SA and currently serves on the board of directors of Arsanis, Inc., Avitide, Inc. and GenKyoTex SA. Claudio Nessi joined NeoMed Management in 2001 and became a Partner in 2004. He has 18 years of experience of venture capital investing in healthcare in Europe and the US. Claudio heads NeoMed’s operations in Switzerland. Previously Claudio was a Venture Partner with Genevest Consulting Group SA, Geneva. He has academic research experience in molecular biology from the Max Planck Institute and the University of Connecticut.

Giovanni Leo serves as Venture Partner at Innogest Capital. He has been VP R&D of St Jude Medical since the acquisition of Endosense in 2013 which he co-founded to develop novel technology for the catheter ablation treatment of cardiac arrhythmias. Prior to Endosense, Giovanni was the director of the Geneva offices for Acrostak Corp., a Boston-Scientific funded medical device company that developed the only European system for vascular brachytherapy. He was also co-founder of Isotopes and Metals Ltd., an emerging medical device company focused on technology for prostate and gynecological brachytherapy. Giovanni previously held a software quality manager position at LeCroy Corp. as well as a CERN fellowship in the Accelerator Technology, Industrial Controls Group. Giovanni earned an Executive MBA in Management and Corporate Finance from the HEC of Lausanne, following a degree in management engineering from Politecnico of Milano, Italy.

Degree in Chemical Sciences at Institut Químic de Sarrià, Barcelona 2000. PhD in Organic Chemistry, Barcelona 2012. Dr. Arad has 15 years of experience in the biomedical field. After a period developing pharmaceutical compounds and photosensitizers for Cancer Photodynamic Therapy, he has developed materials for the medical devices industry: biopolymers and their formulations for controlled drug release applications, lubricious coatings and radiopaque materials for endovascular catheters, chemical enhancement of biomaterials for aortic percutaneous valves and advanced adhesives for medical applications. In the last 7 years he has been leading several projects of medical devices (mainly drug eluting stents and thrombus aspiration catheters) for interventional cardiology applications. He has also been working as chemical research director for a consolidated medical device company.